NextCure FDA accepts IND for ADC LNCB74; Phase 1 trial to start

NextCure, Inc.

FDA accepted IND for LNCB74, a B7-H4-targeting antibody-drug conjugate (ADC).
Phase 1 trial will evaluate LNCB74 for multiple cancers.
LNCB74 developed in partnership with LigaChem Biosciences under co-development agreement.
NextCure CEO Michael Richman highlighted differentiation from other B7-H4 ADCs.
IND acceptance allows NextCure to proceed with clinical development.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.